Moleculera Labs and General Genomics Form Strategic Alliance to Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric Disorders
Retrieved on:
Tuesday, July 26, 2022
Patient, Algorithm, CLIA, Knowledge, Brain, University, Anxiety, ASD, Intelligence, Physician, Pediatrics, Autoantibody, Doctor of Philosophy, PANDAS, Psychiatry, CEO, Research, Degenerative disease, University of Oklahoma Health Sciences Center, Phobia, Lists of diseases, Probability, Artificial intelligence, GGI, Medicine, Risk, Plasma protein binding, COLA, ADD/ADHD, Rapid eye movement sleep behavior disorder, Dysthymia, GE, General Electric, Central nervous system, MBA, Disease, Genomics, Precision medicine, Autism, Depression, Biology, Entrepreneurship, Engineering, Tic disorder, Infection, AI, Basal ganglia, Medical device, Pharmaceutical industry
OKLAHOMA CITY, July 26, 2022 /PRNewswire/ -- Moleculera Labs, Inc. (Moleculera) and General Genomics, Inc. (GGI) announce the formation of a strategic alliance between the two companies.
Key Points:
- OKLAHOMA CITY, July 26, 2022 /PRNewswire/ -- Moleculera Labs, Inc. (Moleculera) and General Genomics, Inc. (GGI) announce the formation of a strategic alliance between the two companies.
- Moleculera Labs, Inc. is a precision medicine company focused on identifying the underlying root of neurologic, psychiatric, and behavioral disorders.
- General Genomics, Inc. is a cutting-edge bioinformatics, AI and machine learning organization founded by former General Electric (GE) and Baker Hughes AI engineers.
- Moleculera Labs is a precision medicine company focused on understanding the biological roots and testing for autoimmune neuropsychiatric disorders.